



23 September 2015

ASX ANNOUNCEMENT

Green Whistle receives regulatory approval in Singapore

Medical Developments International Limited (ASX:MVP) is delighted to announce that it has received approval from the Health Sciences Authority of Singapore to market and sell its inhaled analgesic product, 'Penthrox' for trauma and associated pain, as well as pain in surgical procedures in adults.

This approval gives MVP's partner in Singapore, Link Healthcare Singapore Pte. Ltd the opportunity to sell Penthrox effective immediately.

During the course of getting Penthrox approved in Singapore, MVP used the results of a "Head to Head" clinical trial against Tramadol conducted in Singapore Ambulance, to prove Penthrox is preferred in these clinical settings.

MVP CEO, Mr. John Sharman said "Singapore is an important market in the Asian region and has a population of 5.2 million people. This approval is another important step in establishing a global footprint for Penthrox. MVP is hopeful further country approvals to sell Penthrox will be achieved in the coming months."

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
0414383593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
03 9547 1888

About Pentrox

'Pentrox' is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. 'Pentrox' has been used safely and effectively for more than 30 years in Australia with excess of 5.0 million units sold. There is growing interest in 'Pentrox' being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast acting minor trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About Link Healthcare (Australia, New Zealand, Southern Africa, Singapore, Hong Kong & Japan)

LINK Healthcare is a privately owned specialist pharmaceutical and medical technologies business. LINK's mission is to strive for excellence in the marketing of a vitally important and unique range of specialist products that enhance the well-being of people throughout the regions of Australia, New Zealand, Asia and Southern Africa.

LINK provides exceptional regulatory, sales, marketing, customer service and supply chain infrastructure and is partnered with major blue chip pharmaceutical companies from around the world, allowing the company to offer a unique and substantial portfolio of 'medicine that matters.'

LINK Healthcare has an extensive range of prescription pharmaceuticals in essential therapeutic areas including Allergy, Anaphylaxis, Analgesia/Anaesthesia, Anti-infective, Anti-retroviral, Cardiology, Endocrinology, ENT, Gastroenterology, Intensive care, Metabolic disease, Neurology, Oncology, Orphan Drugs, Palliative care, Psychiatry, Radiography, Transplantation and Toxicology.

Please contact LINK Healthcare on + 61 (2) 8401 9777

Corporate and Media Enquiries:

Mr John Bacon

Chairman